Professor Zhengming Chen qualified in medicine at Shanghai Medical University in 1983 (now Fudan University), and gained his DPhil in Epidemiology at the University of Oxford in 1993. He was appointed as Professor of Epidemiology by the University of Oxford in 2006. He is now the Director of the China Programs at the Oxford University’s Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) and co-executive director of the China Oxford Centre for International Health Research. His main researches focus on the environmental and genetic causes of chronic disease, evidence-based medicine and evaluation of widely practicable treatments for chronic diseases (such as IHD, stroke and cancer) as well as efficient strategies for chronic disease control in developing countries. Over the past 20 years, he has led several large randomised trials in heart disease (eg, COMMIT/CCS-2), stroke (eg, CAST) and cancer and 3 cohort studies involving >750,000 individuals. Since 2003 he has been the lead principal investigator in the UK for the China Kadoorie Biobank (CKB) prospective study of 0.5 million adults. He leads a research team in Oxford which is responsible for study design and development of procedures and IT systems for the CKB, and for central data management, curation and detailed analyses. He is an honorary professor of Peking Union Medical College and Fudan University in China.
Professor Liming Li completed his medical training M.D and M.P.H. at Beijing Medical University, where he later went on to become Dean and Professor. He is currently chair of board & Executive Vice-President of the Chinese Academy of Medical Sciences (CAMS) & the Peking Union Medical College (PUMC) and a Professor of Epidemiology at the School of Public Health, Peking University. He was the founding director of the Chinese Centre for Disease Control and Prevention (China CDC). He is also President of Chinese Epidemiology Association, President of the National Chronic Disease Committee of the Ministry of Health of China, and member of expert committee for the WHO West Pacific Region. His academic research has focussed on the treatment and prevention of hypertension, genetic epidemiological studies of cardiovascular disease, environmental epidemiology and twin studies of non-communicable diseases, as well as quality of life among the elderly in China, the prevention and control of non-communicable diseases, and public health policy and evidence-based decision making. He has been instrumental in establishing and directing a number of large research projects. He is the principal investigator in China for the China Kadoorie Biobank prospective study. At CAMS, he has led the China-Oxford Centre for International Health Research based at the Fuwai Hospital, which facilitates the large collaborative research projects between Oxford and CAMS.